RT Journal Article
SR Electronic
T1 <sup>18</sup>F-FPRGD2 PET/CT Imaging of Integrin α<sub>v</sub>β<sub>3</sub> in Renal Carcinomas: Correlation with Histopathology
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 361
OP 364
DO 10.2967/jnumed.114.149021
VO 56
IS 3
A1 Nadia Withofs
A1 Nicolas Signolle
A1 Joan Somja
A1 Pierre Lovinfosse
A1 Eugène Mutijima Nzaramba
A1 Frédéric Mievis
A1 Fabrice Giacomelli
A1 David Waltregny
A1 Didier Cataldo
A1 Sanjiv S. Gambhir
A1 Roland Hustinx
YR 2015
UL http://jnm.snmjournals.org/content/56/3/361.abstract
AB This study aimed to correlate 18F-FB-mini-PEG-E[c(RGDyK)](2) (18F-FPRGD2) uptake to integrin αvβ3 expression and angiogenesis in renal tumors. Methods: 18F-FPRGD2 PET/CT was performed on 27 patients before surgical resection (median 4 d) of a renal mass. The 18F-FPRGD2 uptake was compared with integrin αvβ3, CD31, CD105, and Ki-67 using immunohistochemistry; with placental growth factor and vascular endothelial growth factor receptors 1 and 2 using reverse transcription polymerase chain reaction; and with vascular endothelial growth factor A isoforms using enzyme-linked immunosorbent assay. Results: Overall, 18F-FPRGD2 uptake significantly correlated (P &lt; 0.0001) with integrin αvβ3 expression in renal masses. However, it correlated only with integrin αvβ3-positive vessels in the group of papillary carcinomas whereas it correlated with integrin αvβ3 expression by tumor cells in the clear cell carcinoma group. Conclusion: 18F-FPRGD2 uptake reflects the expression of integrin αvβ3 in renal tumors but represents angiogenesis only when tumor cells do not express the integrin.